Medical Oncology

UPMC

Questions discussed in this category

How do you approach adjuvant therapy in patients who have a poor clinical response to neoadjuvant endocrine therapy?

No prior chemotherapy.

Do you pursue testing for ERBB2 mutations in patients with metastatic breast cancer who are clinically HER2-negative by IHC and FISH?

If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib?

1 Answer available

What factors do you consider when you are deciding whether to recommend endocrine therapy for a woman who has had a mastectomy for DCIS for contralateral breast cancer risk reduction?

1 Answer available

How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

1 Answer available

What is the upper limits of anthracycline dose you are willing to give in a treatment-refractory metastatic breast cancer patient if the patient is responding to salvage weekly adriamycin after progression on multiple prior regimens?

Patient has hormone-refracatory disease, had high visceral burden (pulmonary mets, bone, lymph). Progressed on taxane, xeloda, gemcitabine. Now ...

1 Answer available

How do you treat HER2-equivocal breast cancer in the neoadjuvant setting?

What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?

1 Answer available

Do you have a certain size threshold below which you change chemotherapy recommendations for a small, triple negative breast cancer?

(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

N. Engl. J. Med., 2017-07-13

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Journal of the National Cancer Institute, 2010-07-07

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

J Natl Cancer Inst, 2006 Jul 5

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

J. Natl. Cancer Inst., 2010-07-07

Tamoxifen and the factor V Leiden mutation.

J. Clin. Oncol., 2003-10-01

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.

Clin. Cancer Res., 2018 Mar 26

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.

Medical Oncology

UPMC

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology